SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Strong R&D investment, advanced manufacturing technologies, and supportive government policies accelerate global API production growth.Austin, Texas, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Small Molecule ...
BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart ...
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at ...
- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - “We are thrilled to showcase our preclinical and Phase 1 ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB resulting in the inhibition of the oncogenic MYB protein and potential cell ...
GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase 2 ...
The MarketWatch News Department was not involved in the creation of this content. BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback